Heterogeneity of Regional Brain Atrophy Patterns Associated with Distinct Progression Rates in Alzheimer’s Disease

We aimed to identify and characterize subtypes of Alzheimer’s disease (AD) exhibiting different patterns of regional brain atrophy on MRI using age- and gender-specific norms of regional brain volumes. AD subjects included in the Alzheimer's Disease Neuroimaging Initiative study were classified into subtypes based on standardized values (Z-scores) of hippocampal and regional cortical volumes on MRI with reference to age- and gender-specific norms obtained from 222 cognitively normal (CN) subjects. Baseline and longitudinal changes of clinical characteristics over 2 years were compared across subtypes. Whole-brain-level gray matter (GM) atrophy pattern using voxel-based morphometry (VBM) and cerebrospinal fluid (CSF) biomarkers of the subtypes were also investigated. Of 163 AD subjects, 58.9% were classified as the “both impaired” subtype with the typical hippocampal and cortical atrophy pattern, whereas 41.1% were classified as the subtypes with atypical atrophy patterns: “hippocampal atrophy only” (19.0%), “cortical atrophy only” (11.7%), and “both spared” (10.4%). Voxel-based morphometric analysis demonstrated whole-brain-level differences in overall GM atrophy across the subtypes. These subtypes showed different progression rates over 2 years; and all subtypes had significantly lower CSF amyloid-β1–42 levels compared to CN. In conclusion, we identified four AD subtypes exhibiting heterogeneous atrophy patterns on MRI with different progression rates after controlling the effects of aging and gender on atrophy with normative information. CSF biomarker analysis suggests the presence of Aβ neuropathology irrespective of subtypes. Such heterogeneity of MRI-based neuronal injury biomarker and related heterogeneous progression patterns should be considered in clinical trials and practice with AD patients.

[1]  Anders M. Dale,et al.  An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest , 2006, NeuroImage.

[2]  E. Masliah,et al.  Plaque‐Only Alzheimer Disease is Usually the Lewy Body Variant, and Vice Versa , 1993, Journal of neuropathology and experimental neurology.

[3]  C. Jack,et al.  Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers , 2013, The Lancet Neurology.

[4]  C. Jack,et al.  MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease , 1992, Neurology.

[5]  C. Jack,et al.  Application of the National Institute on Aging–Alzheimer’s Association AD criteria to ADNI , 2013, Neurology.

[6]  Nick C Fox,et al.  The clinical use of structural MRI in Alzheimer disease , 2010, Nature Reviews Neurology.

[7]  Brigitte Landeau,et al.  Intrinsic Connectivity Identifies the Hippocampus as a Main Crossroad between Alzheimer’s and Semantic Dementia-Targeted Networks , 2014, Neuron.

[8]  Benjamin J. Shannon,et al.  Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory , 2005, The Journal of Neuroscience.

[9]  C. Jack,et al.  Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.

[10]  C. Jack,et al.  Alzheimer's Disease Neuroimaging Initiative (ADNI) , 2010, Neurology.

[11]  Nicola Toschi,et al.  Relevance of magnetic resonance imaging for early detection and diagnosis of Alzheimer disease. , 2013, The Medical clinics of North America.

[12]  Hardeep Singh,et al.  Missed and Delayed Diagnosis of Dementia in Primary Care: Prevalence and Contributing Factors , 2009, Alzheimer disease and associated disorders.

[13]  Kazuhiko Yanai,et al.  Non-invasive assessment of Alzheimer's disease neurofibrillary pathology using 18F-THK5105 PET. , 2014, Brain : a journal of neurology.

[14]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[15]  D. Y. Lee,et al.  A normative study of total scores of the CERAD neuropsychological assessment battery in an educationally diverse elderly population , 2014, International Psychogeriatrics.

[16]  L A Hansen,et al.  The importance of neuritic plaques and tangles to the development and evolution of AD , 2004, Neurology.

[17]  J. Brewer.  Fully-Automated Volumetric MRI with Normative Ranges: Translation to Clinical Practice , 2009, Behavioural neurology.

[18]  Robert A. Dean,et al.  Florbetapir positron emission tomography and cerebrospinal fluid biomarkers , 2015, Alzheimer's & Dementia.

[19]  M. Murray,et al.  Regional patterns of atrophy on MRI in Alzheimer’s disease: Neuropsychological features and progression rates in the ADNI cohort , 2013 .

[20]  Benjamin Thyreau,et al.  A longitudinal study of age‐ and gender‐related annual rate of volume changes in regional gray matter in healthy adults , 2013, Human brain mapping.

[21]  J. Morris,et al.  The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals , 2008, Cerebral cortex.

[22]  Kiralee M. Hayashi,et al.  Dynamics of Gray Matter Loss in Alzheimer's Disease , 2003, The Journal of Neuroscience.

[23]  W. Kukull,et al.  Accuracy of the Clinical Diagnosis of Alzheimer Disease at National Institute on Aging Alzheimer Disease Centers, 2005–2010 , 2012, Journal of neuropathology and experimental neurology.

[24]  Kader Karli Oguz,et al.  Hippocampal atrophy correlates with the severity of cognitive decline , 2006, International Psychogeriatrics.

[25]  Sang Won Seo,et al.  Anatomical heterogeneity of Alzheimer disease , 2014, Neurology.

[26]  Ki Woong Kim,et al.  A normative study of the CERAD neuropsychological assessment battery in the Korean elderly , 2004, Journal of the International Neuropsychological Society.

[27]  Akram Bakkour,et al.  The effects of aging and Alzheimer's disease on cerebral cortical anatomy: Specificity and differential relationships with cognition , 2013, NeuroImage.

[28]  D. Y. Lee,et al.  Normative study of the Stroop Color and Word Test in an educationally diverse elderly population , 2008, International journal of geriatric psychiatry.

[29]  Joanne S. Robertson,et al.  Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study. , 2015, Journal of Alzheimer's disease : JAD.

[30]  Philip S. Insel,et al.  Development and assessment of a composite score for memory in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) , 2012, Brain Imaging and Behavior.

[31]  M. Weiner,et al.  Relationships between biomarkers in aging and dementia , 2009, Neurology.

[32]  Thomas E. Nichols,et al.  Preventing Alzheimer’s disease-related gray matter atrophy by B-vitamin treatment , 2013, Proceedings of the National Academy of Sciences.

[33]  C. Jack,et al.  MRI patterns of atrophy associated with progression to AD in amnestic mild cognitive impairment , 2008, Neurology.

[34]  J. D. Pauker.  Constructing overlapping cell tables to maximize the clinical usefulness of normative test data: rationale and an example from neuropsychology. , 1988, Journal of clinical psychology.

[35]  D. Head,et al.  Amyloid Plaques Disrupt Resting State Default Mode Network Connectivity in Cognitively Normal Elderly , 2010, Biological Psychiatry.

[36]  Cees Jonker,et al.  Medial temporal lobe atrophy and memory dysfunction as predictors for dementia in subjects with mild cognitive impairment , 1999, Journal of Neurology.

[37]  Nick C Fox,et al.  The Alzheimer's disease neuroimaging initiative (ADNI): MRI methods , 2008, Journal of magnetic resonance imaging : JMRI.

[38]  Frederik Barkhof,et al.  Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion , 2002, The Lancet Neurology.

[39]  K. Welsh-Bohmer,et al.  Norms for CERAD Constructional Praxis Recall , 2011, The Clinical neuropsychologist.

[40]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[41]  Kazuhiko Yanai,et al.  Non-invasive assessment of Alzheimer ’ s disease neurofibrillary pathology using 18 F-THK 5105 PET , 2014 .

[42]  Masayuki Matsuda,et al.  Four subgroups of Alzheimer's disease based on patterns of atrophy using VBM and a unique pattern for early onset disease , 2006, NeuroImage.

[43]  Nick C Fox,et al.  The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease , 2011 .

[44]  Cindee M. Madison,et al.  Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. , 2013, Brain : a journal of neurology.

[45]  R. Katzman.,et al.  Senile Dementia of the Alzheimer Type Without Neocortical Neurofibrillary Tangles , 1987, Journal of neuropathology and experimental neurology.

[46]  Z. Khachaturian.  Alzheimer's & Dementia: The Journal of the Alzheimer's Association , 2008, Alzheimer's & Dementia.

[47]  David A Wolk,et al.  Dysexecutive versus amnesic phenotypes of very mild Alzheimer's disease are associated with distinct clinical, genetic and cortical thinning characteristics , 2010, Journal of Neurology, Neurosurgery & Psychiatry.

[48]  Philip S. Insel,et al.  A composite score for executive functioning, validated in Alzheimer’s Disease Neuroimaging Initiative (ADNI) participants with baseline mild cognitive impairment , 2012, Brain Imaging and Behavior.

[49]  J. Morris,et al.  The diagnosis of dementia due to Alzheimer’s disease: Recommendations from the National Institute on Aging-Alzheimer’s Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[50]  James F. Malec,et al.  The Auditory-Verbal Learning Test (AVLT): Norms for ages 55 years and older. , 1990 .

[51]  A. Burns.  Clinical diagnosis of Alzheimer's disease , 1991 .

[52]  L. McEvoy,et al.  Predicting MCI outcome with clinically available MRI and CSF biomarkers , 2011, Neurology.

[53]  C. Jack,et al.  Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study , 2012, The Lancet Neurology.

[54]  J. Crowley,et al.  Age-Expanded Normative Data for the Ruff 2&7 Selective Attention Test: Evaluating Cognition in Older Males , 2012, The Clinical neuropsychologist.

[55]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[56]  M. Albert,et al.  Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease , 2011, Alzheimer's & Dementia.

[57]  R. Petersen,et al.  Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study , 2011, The Lancet Neurology.

[58]  Sebastien Ourselin,et al.  Imaging endpoints for clinical trials in Alzheimer’s disease , 2014, Alzheimer's Research & Therapy.

[59]  R. Petersen,et al.  Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects , 2009, Annals of neurology.